Tlhaloso
Tofacitinib ea rona ea mahareng e boetse e tsejoa e le cis-1-benzyl-4-methyl-3-methylaminopiperidine dihydrochloride mme e na le nomoro ea CAS 1062580-52-2.Bohareng ke motsoako o ka sehloohong tlhahisong ea tofacitinib, sethethefatsi se sebelisetsoang ho phekola ramatiki ea lefu la masapo, psoriatic arthritis le ulcerative colitis.Joalo ka li-intermediate tsa bohlokoa ho kopanngoeng ha tofacitinib, lihlahisoa tsa rona li bohlokoa ho bafuputsi ba meriana le bahlahisi.
Motsoako ona oa bohareng o entsoe ka hloko ho netefatsa boemo bo phahameng ka ho fetisisa ba bohloeki le ho tsitsa.Ka mekhoa ea rona ea morao-rao ea tlhahiso le mehato e thata ea ho laola boleng, u ka tšepa hore li-intermediate tsa rona tsa tofacitinib li finyella litekanyetso tse phahameng ka ho fetisisa tsa indasteri bakeng sa bohloeki le botsitso.
Tofacitinib Intermediate (3R, 4R) -1-Benzyl-3- (Mmethylamino) -4-Mmethylpiperidine DiHClide e na le mefuta e mengata ea likopo, e etsang hore e be letlotlo la bohlokoa lipatlisisong tsa meriana le lik'hemik'hale.Hore na o etsa lipatlisiso tsa thuto kapa o nts'etsapele meriana, metsoako ea rona e bohareng e fana ka litharollo tse tšepahalang le tse baballang litlhoko tsa hau tse ikhethileng.
Khetha Rona
JDK e na le lisebelisoa tsa tlhahiso ea maemo a pele le lisebelisoa tsa taolo ea boleng, tse netefatsang phepelo e tsitsitseng ea li-intermediate tsa API.Sehlopha sa litsebi se tiisetsa R&D ka sehlahisoa.Khahlanong le bobeli, re batla CMO & CDMO 'marakeng oa lapeng le oa machabeng.
